Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Nutrien Ltd (NTR) Price & Performance

Abeona Therapeutics IncTrade
Nutrien LtdTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Nutrien Ltd — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Nutrien Ltd trades at $66.6 (market cap $32.05B). The key difference: Nutrien Ltd is far larger — about 76.1× Abeona Therapeutics Inc's market cap, and Nutrien Ltd pays a 3.27% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEONTR
Market Cap
$421.19M$32.05B
Sector
HealthBasic Materials
52-Week High
$7.45$83.94
52-Week Low
$4.17$53.64
Enterprise Value
$276.10M$43.86B
Dividend Yield
3.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

Nutrien Ltd

Nutrien (NTR) trades at $66.85, up 0.81% today, with a bearish technical signal despite neutral oscillators. Recent Q2 2026 earnings missed EPS estimates but beat on revenue, driven by higher potash prices. The company maintains a stable dividend of $0.55 per share and shows improving net income margins, though cash flow trends have weakened. Analyst consensus is bullish with a $76.17 price target, highlighting structural advantages in nitrogen assets.

The outlook is mixed: strong fundamentals and analyst support suggest upside, but technical weakness and volatile earnings pose risks. Key opportunities include exposure to agricultural cycles and cost advantages; risks involve input cost pressures and execution challenges in a competitive fertilizer market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Nutrien Ltd

Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.

Read more on NTR